Target intelligence / Profile preview

Non-muscle myosin II (NM II)

Target
NM II
Molecular classification
Motor protein, Enzyme (ATPase activity), Cytoskeletal protein, Molecular motor
01

Overview

Non-muscle myosin II is a major cytoskeletal molecular motor protein complex, responsible for ATP-dependent contractile force generation in nearly all eukaryotic cells outside of muscle tissue[3][4][5][6]. Structurally, it is a hexamer composed of two heavy chains (encoded by MYH9/10/14 for isoforms NM IIA/IIB/IIC), two essential light chains, and two regulatory light chains[3][4][5][6]. It dynamically assembles into bipolar filaments that interact with actin filaments to drive processes such as cytokinesis, cell migration, shape change, mechanotransduction, and maintenance of tissue architecture[3][4][5][6][1]. Distinct NM II isoforms (A, B, C) have specialized and overlapping cellular functions, with mutations or dysregulation implicated in numerous diseases including cancer metastasis, cardiovascular disorders, developmental defects, and specific hereditary syndromes[6][1]. NM II activity and assembly are tightly regulated through phosphorylation of regulatory light chains and various signaling pathways[2][5]. Selective inhibition of non-muscle myosin II is under investigation for conditions involving abnormal cell migration, contractility, or division.

Other names
NM IINM2NMIINonmuscle myosin 2Non-muscle myosin heavy chain II (for isoforms: MYH9/NM IIA, MYH10/NM IIB, MYH14/NM IIC)Non-muscle myosin-2 (alternative hyphenation)Non-muscle myosin II heavy chain
02

Mechanism of action

Inhibition of myosin II ATPase activity (by blebbistatin and related) Blockade of actomyosin contractility/filament formation

03

Biological functions

Cell division (cytokinesis)Cell adhesionCell migration/motilityMechanotransductionContractility and force generationTissue morphogenesisIntracellular traffickingTension maintenance in tissues
04

Disease associations

Cancer (metastasis, cell migration, invasion)Cardiovascular disease (e.g., cardiomyopathy)Neurodevelopmental disordersBleeding disorders (mutations)InflammationKidney disease (MYH9-related disease)Other (epilepsy, hearing loss, etc. depending on isoform)
05

Safety considerations

Inhibition may impair wound healing, tissue repair, or organ developmentPotential effects on heart contractility and blood cell divisionOff-target cytoskeletal effects with broad inhibitors
06

Interacting drugs

Blebbistatin (selective NM II inhibitor)

2 more in the full profile.

07

Biomarkers

MYH9 expression/mutation status (for certain kidney disorders, cancers)NM II isoform protein levels (e.g., in tumor tissue)

Beyond the preview

Go deeper on Non-muscle myosin II (NM II).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-muscle myosin II (NM II).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call